investorscraft@gmail.com

Intrinsic Value of NeoGenomics, Inc. (NEO)

Previous Close$11.67
Intrinsic Value
Upside potential
Previous Close
$11.67

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-06-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2022(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %5.2NaN
Revenue, $510NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m667NaN
Operating income, $m-158NaN
EBITDA, $m-85NaN
Interest expense (income), $mNaN
Earnings before tax, $m-159NaN
Tax expense, $m-15NaN
Net income, $m-144NaN

BALANCE SHEET

Cash and short-term investments, $m438NaN
Total assets, $m1740NaN
Adjusted assets (=assets-cash), $m1302NaN
Average production assets, $m1056NaN
Working capital, $m515NaN
Total debt, $m542NaN
Total liabilities, $m742NaN
Total equity, $m998NaN
Debt-to-equity ratio0.543NaN
Adjusted equity ratio0.435NaN

CASH FLOW

Net income, $m-144NaN
Depreciation, amort., depletion, $m72NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-66NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-19NaN
Free cash flow, $m-47NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m515
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN

Company description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
HomeMenuAccount